Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:2
članak: 7 od 8  
Back povratak na rezultate
Acta Facultatis Medicae Naissensis
2019, vol. 36, br. 2, str. 150-158
jezik rada: engleski
vrsta rada: izvorni naučni članak
objavljeno: 09/09/2019
doi: 10.5937/afmnai1902150A
Creative Commons License 4.0
Procena uticaja lečenja na hormon neuropeptid leptin i rizik od gojaznosti kod žena sa karcinomom dojke u Jordanu
aPrimenjeni univerzitet Al-Balqa, Univerzitetski koledž Al-Zarqa, Departman objedinjenih medicinski nauka, Jordan
bUniverzitet u Jordanu, Fakultet za agrikulturu, Departman za nutricionizam i tehnologiju hrane, Amman, Jordan
cMedicinski centar King Hussein, Departman za opštu hirurgiju, Odeljenje za lečenje kancera dojke, Amman, Jordan

e-adresa: safaa84@bau.edu.jo

Sažetak

Kancer dojke je najčešći životno ugrožavajući maligni tumor kod žena. Malo se zna o vezi između hormona neuropeptida leptina i razvoja karcinoma dojke. Cilj rada je bila procena interaktivne uloge neuropeptida leptina u odnosu na lečenje i menopauzu kod žena sa karcinomom dojke u Jordanu. Opservaciona studija uključila je 398 bolesnica sa karcinomom dojke (starosti od 25 do 65 godina) lečenih na klinikama za karcinom dojke. Eksperimentalna studija je uključila 134 novodijagnostikovane bolesnice sa karcinomom dojke koje nisu prethodno lečene i 262 bolesnice u toku prva tri meseca lečenja kojima je neposredno pre toga dijagnostikovan karcinom dojke. Za kvantitavno određivanje nivoa leptina korišćen je ELISA test. Prevalencija hiperleptinemije - nivo leptina iznad 11,1ng/ml, bila 27% je, dok je srednja vrednost leptina u serumu (ng/ml) u celom uzorku bila 8,5 ± 0,03 i bila je nesignifikatno niža kod bolesnica koje nisu lečene hemoterapijom (7,1 ± 0,05) nego kod bolesnica koje su lečene ovom terapijom (8,6 ± 0,5) i kod novodijagnostikovanih bolesnica (9,2 ± 0,6). Leptin je bio u pozitivnoj korelaciji sa indeksima gojaznosti uključujući BMI, WC, WHpR i WHtR. Kod novodijagnostikovanih bolesnica, leptin je bio u najvišoj korelaciji sa BMI r = 0,38; p ˂ 0,05, dok je kod bolesnica kod kojih je neposredno pre toga bolest bila dijagnostikovana, leptin bio u visokoj korelaciji sa WC ( r = 0,38; p < 0,05). Leptin je bio u pozitivnoj korelaciji sa sa indeksima gojaznosti kod bolesnica sa karcinomom dojke i njegove vrednosti su bile povišene kod žena u menopauzi sa karcinomom dojke. Vrednosti leptina su bile snižene nakon lečenja, te se ovaj hormon može smatrati biomarkerom za prognozu karcimoma dojke i odgovor na lečenje. Zdravstveni radnici treba da obrate više pažnje na ovaj hormon kako bi se poboljšao ishod ove bolesti nakon donošenja dojagnoze i lečenja.

Ključne reči

karcinom dojke; lečenje karcinom; hormon leptin; neuropeptid; gojaznost; postmenopauza

Reference

*** (2000) Obesity, preventing and managing the global epidemic: Report of a WHO Consultation. Geneva: WHO, Technical Report Series No. 894, http://www.who.int/nutrition/publications/obe-sity/en/index.html
Al-Tarawneh, M., Arkoob, K., Al-Nsour, M., et al. (2009) Epidemiology of breast cancer in women in Jordan: Patient characteristics and survival analysis. EMH J, 16: 1032-1040
Al-Zeidaneen, S., Ahmad, M., Al-Ebouse, A. (2015) The risk of malnutrition among breast cancer women as related to their dietary intakes in Jordan. u: 2015 Conference: The 7th Conference on Scientific Research in Jordan, Organized by the Jordan Society for Scientific Research at Middle East University, Amman, Jordan
Al-Zeidaneen, S., Ahmad, M., Al-Ebouse, A., et al. (2017) Interactive role of obesity indices on breast cancer severity in Jordanian women. EJBPS, 4: 637-681
Al-Zeidaneen, S., Ahmad, M., Homa-Ir, A.A. (2017) The Impact of Treatment Exposure on Diabetes Bio-markers among Jordanian Breast Cancer Women: A Connection through FBG, C-Peptide and HOMA-IR. Curr Gynecol Oncol, 15: p. 231-238
Amirkalali, B., Sharifi, F., Fakhrzadeha, H., et al. (2010) Low serum leptin serves as a biomarker of malnutrition in elderly patients. Nutr Res, 30: 314-323
Anubhuti, A.S. (2008) Leptin and its metabolic interactions: An update. Diabetes Obes Metab, 10(11), str. 973-93. Epub Feb 18
Artac, M., Altundag, K. (2012) Leptin and breast cancer: An overview. Med Oncol, 29: 1510-1514
Bouillanne, O., Golmard, J., Coussieu, C., et al. (2006) Leptin a new biological marker for evaluating malnutrition in elderly patients. Eur J Clin Nutr, 61: 647-54
Carroll, P.A., Healy, L., Lysaght, J., et al. (2011) Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer. Mol Carcinog, 50: 643-51
Catalano, S., Marsico, S., Giordano, C. (2003) Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem, 278: 28668-76
Cederholm, T., Arner, P., Palmblad, J. (2003) Low circulating leptin levels in protein-energy malnourished chronically ill elderly patients. J Intern Med, 242: 377-82
Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med, 334(5): 292-5
Garofalo, C., Surmacz, E. (2006) Leptin and Cancer. J Cel Physiol, 207: 12-22
Goodwin, P.J., Ennis, M., Fantus, I.G. (2005) Is leptin a mediator of adverse prognostic effects of obesity in breast cancer. J Clin Oncol, 23: 6037-6079
Han, C., Zhang, H.T., Du, L., et al. (2005) Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine, 26: 19-24
Kahn, B.B., Flier, J.S. (2000) Obesity and insulin resistance. J Clin Invest, 106(4): 473-81
Lee, R.D., Nieman, D.C. (2010) Nutrational Assessment. New York: McGraw-Hill, 5 th ed
Lyoussi, B., Ragala, M., M'guil, M., et al. (2005) Gender-Specific Leptinemia and Its Relationship with Some Components of the Metabolic Syndrome in Moroccans. Clin Exp Hypertens, 4: 377-94
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7): 412-9
Mueller, W.M., Gregoire, F.M., Stanhope, K.L., Mobbs, C.V., Mizuno, T.M., Warden, C.H., Stern, J.S., Havel, P.J. (1998) Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. Endocrinology, 139(2): 551-8
Murakami, T., Yamashita, T., Iida, M., et al. (1997) A short form of leptin receptor performs signal transduction. Biochem Biophys Res Commun, 231: 26-35
Park, H.Y., Kwon, H.M., Lim, H.J., et al. (2011) Potential role of leptin in angiogenesis: Leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med, 33: 95-102
Petridou, E., Papadiamantis, Y., Markopoulos, C., et al. (2000) Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control, 11: 383-391
Stattin, P., Soderberg, S., Biessy, C., et al. (2004) Plasma leptin and breast cancer risk: A prospective study in northern Sweden. Breast Cancer Res Treat, 86: 191-197
Surmacz, E. (2007) Obesity hormone leptin: A new target in breast cancer?. Breast Cancer Res, 9: 301-301
Tessitore, L., Vizio, B., Jenkins, O., et al. (2000) Leptin expression in colorectal and breast cancer patients. Int J Mol Med, 5: 421-427
Wu, M., Chou, C., Chou, Y., et al. (2009) Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer, 100: 578-82
Yun, J., Kimm, H., Jo, J., Jee, S. (2010) Serum leptin is associated with metabolic syndrome in obese and non-obese Korean populations. Metabolism, 59: 424-433
Zamboni, M., Zoico, E., Fantin, F., et al. (2011) Relation between Leptin and the Metabolic Syndrome in Elderly Women. J Gerontol Med Sci, 59: 396-400